Biotech | September 03, 2021
DGCI green lights Biological E for Phase 2/3 trials of its Covid-19 vaccine candidate for children
The trial will be conducted across 10 sites in India
The trial will be conducted across 10 sites in India
This is Omeza’s first Rx product and the first drug/device combination matrix of its kind for chronic wound care
Researchers at the Feinstein Institutes administer extra vaccine doses as part of the NIH funded study
Key trends indicate that AI-based solutions, cloud-based healthcare solutions and digital transformations will be the key in the years to come.
This is the third acquisition by Healthium this year apart from AbGel business in India and VitalCare in the UK
JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis
_256_384.jpeg)
The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio
The Covid-19 pandemic has exposed the divide that exists between rich and developing nations and to address these challenges the World Health Organisation (WHO), has compiled a list of innovative health technologies that aim to bridge the gap
Self-collection devices designed for ease of use and safety
Advance to Phase 3 follows positive interim Phase 1/2 immunogenicity and safety data. The global clinical trial will evaluate vaccine candidate GBP510 against the AZ/Oxford COVID-19 vaccine
Subscribe To Our Newsletter & Stay Updated
